Olmesartán Stada (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Stada, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is employed in the management of hypertension, particularly in adult patients who require blood pressure control. GNH USA supplies Olmesartán Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy (as an adjunct): slows progression of kidney damage associated with diabetes. - Heart failure (off‑label in some regions): may improve symptoms when combined with other heart‑failure therapies. - Stroke prevention (off‑label): contributes to secondary prevention by controlling hypertension. - Chronic kidney disease (off‑label): assists in blood‑pressure management to protect renal function.

Olmesartan Medoxomil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema (swelling of face, lips, tongue) - Hyperkalemia (elevated blood potassium) - Acute kidney injury - Severe hypotension - Liver enzyme elevations - Allergic skin reactions (e.g., rash, Stevens‑Johnson syndrome)

When prescribing Olmesartan Medoxomil, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline creatinine and eGFR, then periodically. - Electrolyte assessment: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: use caution as they may reduce antihypertensive effect and affect renal function. - Hypotension risk: monitor blood pressure after initiation, particularly in volume‑depleted patients. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): heightened risk of kidney injury and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt blood‑pressure reduction and affect renal function. - Lithium: may increase serum lithium levels, risking toxicity. - Cyclosporine or tacrolimus: can raise olmesartan concentrations and affect kidney function. - Diuretics: may enhance hypotensive effect, requiring dose adjustment. - Rifampin: may reduce olmesartan plasma levels, diminishing antihypertensive effect.